<![CDATA[Lenvatinib Dose Reductions Help Sustain Therapy in Endometrial Cancer]]>

Data ReadoutpositivelenvatinibPositive

AI Analysis

Summary

Lenvatinib dose reduction from 20 mg to 14 mg improves patient tolerance and therapy continuation in endometrial cancer treatment, according to clinical experience shared by Dr. Susana Campos.

Clinical Trial Data

Outcome Details

Dose reduction from 20 mg to 14 mg improves therapy tolerability and patient adherence in endometrial cancer

Importance:4/10

Sentiment:

0.60

lenvatinibendometrial cancerdose optimizationdrug tolerabilityclinical management

Related Companies

$ESALY

Read the original article

Published by Cancer Network on August 25, 2026 8:00 PM

Read Original